The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.
about
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceDrug interactions between antiretroviral medications and medications used in the treatment of drug addiction: research needs.Practical considerations for the clinical use of buprenorphine.HIV/AIDS and drug use in China--interactions, impacts, and issues.Liver enzyme induction and inhibition: implications for anaesthesia.Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.Strategies to improve access to and utilization of health care services and adherence to antiretroviral therapy among HIV-infected drug users.Pharmacologic treatments for opioid dependence: detoxification and maintenance options.Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activityDrug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women.Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patientsNon-medical use of opioids among HIV-infected opioid dependent individuals on opioid maintenance treatment: the need for a more comprehensive approach.Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.Drug interactions in the management of HIV infection.Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label studyThe role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations.Medical illness and comorbidities in drug users: implications for addiction pharmacotherapy treatment.Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence.Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.Finding what works: identification of implementation strategies for the integration of methadone maintenance therapy and HIV services in VietnamDrug interactions in the management of HIV infection: an update.Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.Treatment of opioid-dependent pregnant women: clinical and research issues.Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse.Induction effects of ritonavir: implications for drug interactions.Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenanceNevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.Methadone, buprenorphine, and street drug interactions with antiretroviral medicationsMethadone: a review of drug-drug and pathophysiological interactions.The issues around opioid prescribing in HIV-related pain.Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products
P2860
Q27692040-9122A309-DA05-4236-BD3C-59322D71755CQ33640426-9ECED78E-7151-47D5-B069-CF269A77FFE9Q33774853-C6554B05-2D8A-49E7-B239-0CD5DAFD5D78Q34119447-FD46A827-FA75-4CA0-A85E-20201C269485Q34487131-E3172D71-940E-4F20-AD61-7864F81C3B93Q34604652-61DB2DBE-C8FD-4E7C-AA38-85D1993AC3D3Q34633457-57FE73F7-B315-44F9-8855-FB5AD9B8B33EQ35000765-3099C0A1-D63F-4D35-BB0B-89DF0035A561Q35148360-1B325B25-575E-4BEC-AC00-BBB05AD7800BQ35454866-CC69848B-BEF7-49C7-84A2-03C69FF94244Q35672530-B43271F1-5192-42D4-80A6-674B5A7D4B72Q35684822-565637D8-D6BD-4618-AD47-10E6097472C7Q35738851-53F2D419-EB38-4495-BFC4-A5391F3FF60CQ35738878-E3992D6D-EEC2-4935-9B90-7E1797E5B6AAQ35738885-E866FD26-DCA8-484E-908E-80403840A88AQ35777089-A5501244-1D09-40A4-967E-D9A43444C2D5Q35906594-610BA9CC-98D0-4C06-87E3-A651155B800CQ36066083-910E6C54-182B-4AAB-B2B3-23CB6DFA3EA7Q36105831-25518F0F-0D37-43C2-836A-7A3630CD8420Q36249104-3E4D83FF-FC7A-4279-90BB-F303E73137D9Q36311018-0E96962A-03F7-40F2-A509-AAD4CCA22B25Q36543096-5143204C-976B-4B92-A246-17B58C4139BBQ36637864-D1B415CF-5066-4714-A003-05375805244EQ36641870-F7772EF4-A100-4829-BFC9-BB19FE8122F9Q36641884-52C654CA-858B-4FC3-A9B8-144AB448AE77Q36815377-9DE11947-4DB5-4942-8333-A93361C11D7EQ37000733-AA828570-11E6-4915-9083-C042BCAF17A5Q37045335-F5FFD442-017E-4B14-88C6-D26095C155E3Q37052827-C026E7CF-A762-48E5-B0C0-06C70034952AQ37076673-0E6E8D09-EF46-4AE0-B9FD-53563D4977BCQ37125615-9950CC92-44E2-4576-8A7B-B511AEB096F8Q37199533-5FD551CA-585D-4DBB-A62F-045FD362DD4FQ37325606-AE8CAC7C-BB43-43F2-A11F-DE8D958E1710Q37335799-B471F4AC-DE11-4C0F-9983-EBE386113BD5Q37598731-1D272270-3F45-4DAC-A09B-86E93CEDA40CQ37763615-9E294D9F-9F55-4E2C-B1B6-411BB16B8369Q37950478-10F9326F-AF1B-4DB4-A8A5-15D34E951B00Q38198106-CB862C4A-3900-44A4-8624-C2ACCE6306B3Q38435908-03EDB241-756A-4661-8131-9613E92E8CF3Q38513275-33633017-811F-4471-9F84-C078B3BB265F
P2860
The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
The protease inhibitor lopinav ...... methadone-maintained patients.
@en
The protease inhibitor lopinav ...... methadone-maintained patients.
@nl
type
label
The protease inhibitor lopinav ...... methadone-maintained patients.
@en
The protease inhibitor lopinav ...... methadone-maintained patients.
@nl
prefLabel
The protease inhibitor lopinav ...... methadone-maintained patients.
@en
The protease inhibitor lopinav ...... methadone-maintained patients.
@nl
P2093
P356
P1476
The protease inhibitor lopinav ...... methadone-maintained patients.
@en
P2093
Elinore F McCance-Katz
Gerald Friedland
Peter Jatlow
Petrie M Rainey
P304
P356
10.1086/376907
P407
P577
2003-08-01T00:00:00Z